Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study
Open Access
- 10 September 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 9 (1), 322
- https://doi.org/10.1186/1471-2407-9-322
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancerInternational Journal of Cancer, 2008
- Advances in the Treatment of Breast CancerClinical Pharmacology & Therapeutics, 2007
- Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancerCancer, 2007
- Novel functions of TIMPs in cell signalingCancer and Metastasis Reviews, 2006
- High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinomaBreast Cancer Research and Treatment, 2005
- Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast CancerMolecular & Cellular Proteomics, 2003
- The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.2000
- Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancerBritish Journal of Cancer, 1999
- Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.1989
- Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. workshop, held on 16–17 March, 1979, in the Netherlands Cancer InstituteEuropean Journal of Cancer (1965), 1980